Phekolo ka ARV (ARV Treatment)

Anti-retroviral (ARV) drugs often have the capacity to improve the health of HIV/AIDS patients. But ARV drugs come with a high cost that most poor countries cannot afford. Lesotho cannot afford to subsidise the purchase and use of ARV drugs. There are no ARV drugs in Lesotho, not today, and not tomorrow. Apparently,
The policy of providing ARV drugs policy guarantees a longer survival for HIV+ individuals, minimising the impact of the epidemic on the population groups infected, particularly those in productive age ones. Moreover, the universal access program, together with other initiatives, such as the more widespread use of chemoprophylaxis for the main opportunistic infections and the different types of care available (Day Hospital and Home Care), has allowed a decrease in the need for hospital admissions, with a consequent reduction of costs, as well as a fall in the frequency of opportunistic infections. As for the decrease in deaths, a marked reduction in AIDS-related mortality has been observed in recent years. In 1995, the AIDS death rate was 12.2 per 100,000 population; in 1999, it had dropped to 6.3/100,000 population, a reduction of approximately 50%. In large urban centres such as Sao Paulo and Rio de Janeiro (which account for more than 31% of the known AIDS cases in [Brazil]), the decrease in mortality has been even more marked, of approximately 70% (SP - 54%, Rio - 73%) in the period 1995-2000 (data up to August 2000).
Yeah, a pipe dream. How can a hungry person spend sparse earnings on medicine that may help? In walks $100 million donated by Bristol Myers. Thanks, folks. Some of that money was used to launch Senkatana Center, one of five HIV/AIDS treatment support programs in the southern African region. Bristol-Myers Squibb has made a $100 million commitment to go to war against HIV/AIDS in this region that is often referred to as the hardest-hit in the world. Well, what does one say, apart from a heartfelt Rea leboha!
[ Read on... ]